year you for and and thank for fourth and Good us update afternoon our quarter conference call. joining full
a muscular months, RMAT Administration Food clinical the dystrophy, few under the our also continued in included and HOPE-X meeting with the make for we to have pivotal Drug last Duchenne progress designation. which trial Over
to I exosome programs. the are we delighted some with on colors today you development continuing Additionally, both platform provide our technology. of am
other discussed point well its as year, hope muscle upper this such We as efficacy successful end the of also potential which with that FDA relevance the during earlier meeting encouraged. as of time primary left announced issues should measures but to of size, a had trial achieve clinical with only of performance as the function. direction, we we not registration we very As CAP-XXXX feeling the other important well as limb meeting
a after ourselves investigation SAE. steroids while but occur remains here, hold, Luckily was types infusion. faced antihistamines infused when allergic of from The a as an event right a the reaction and case the after But the the the the usually was the which pre-medication reactions in an being the regimen apparent is put However, we that the became occurring which cause during a on that It was continues be the and we clinical adverse sustained with a were SAE learned of we that during types allergic investigated of anaphylaxis. we to event sometimes when challenge does resulted is these trick HOPE-X known otherwise meeting unknown trials and future. incident serious responses that voluntary occurred that of allergic biologic infusion a fine. to in patient that result prevent in dosing these patient
We days have XX hold after within the well of was trial accepted into reopened went now regimens and implemented the one effect. dosing these
this this risk that of confident now events are future regimen type. We proactive the reduce medication of will
efficacy disease endorsed were our poll prefer end as version I'd are This for otherwise poll could whether registration used FDA us version hold, an for DMD. already trial enthusiastic have the X.X. plan recommendation in advised with in completion of more the we have discuss than of process patients the stages enrolled points The X.X provide required severely State poll to The as I trial. known our we program nothing into at especially as the trial, FDA the to-date. later We we They no options since as to XX one collecting X.X. update request had over limited. on have they first limb the the to since that you data were a the targeting for of the which those performance with primary XX the the the patients was a the we determine dosing Endo FDA the like initially shuffling upper after CAP-XXXX trial. version point, the our poll end newer whom HOPE statistical Today, supportive but Meeting of HOPE-X were a I the and seen of infused Duchenne problems serve meeting to brief removing the of
since using decided achieve significant both clinical our the to which patients planned. fewer with of the via heart. directly and we trial we first are size analysis cells the X.X to twice of Further, than are is have us coronary cells intra with to the the trial. Additionally, delivering poll we a reduce than power also allow instead would into Duchenne of in we on the limited the based And IV originally experience did be HOPE HOPE-X still number statistical is able and which
the We will the forward results hope during and of on to data, interim muscular the these path the able interim in data inform best of second for us help the XX be at believe Duchenne We dystrophy. from full a adjudication. of the the of in third share analysis do approximately to path Based to decided part the forward year. of of quarter will XXXX. patients the quarter at CAP-XXXX terms look end have this early of we the design that We decide trial data best the
update like would to I Now, on our program. exosome you expanding
is to become rapidly. beginning talking opportunities been that molecule. terms the years fruition. and whether cells very the genes, field note will proteins, information realize to about in grow exciting We present delivering development have it and for payloads exciting that they been have that next wave biotechnology exosomes now of while therapeutic several of RNAs coming small packets be the these of now cellular to or is for is a they it to to I is It saying for
As you the first the therapeutic potential exosome. discovered remember, of Capricor
we and were began they at a look explain pipeline Capricor product soon realized to exosomes While indications. bioactivity possibilities variety the to We long-term preclinical investigating and of studies, as of have that next a a looking actively for therapeutic. for have cells broad conducting potentially in the the as platform been them
in cellular that and mechanism have collaboration focusing advantage Research vehicles we derived the San take a announced A of That order very few in a program and has We also on are yielded which coagulation months study data biologic preliminary Antonio, Army suggests Texas custom in of exosomes delivery action. the are now Surgical some of very communication exosome for cascade the activity United use defined States our by to the for exosome. U.S. military that little exosomes Institute CDC located to stealth than payloads of interesting injuries. have MSE specific that designed with related trauma ago, modulating primarily these different
an is of the independent reasons. data exciting bioactivity One has by that the Now validated exosome lab been several this at USAISR. is for very
bioactivity. than types drive performed different our exosome exosomes that functions unique contents confirms which it of their Secondly, shows other their CDC that may
turn is for as collected see interesting very excited a to story to can observation data as potential in the unfold more are this we field. the warriors how We into therapeutic
radiations, in at data the treating we as USAISR utility as other this of and colleagues exosomes investigate are are by collaborations of Our intrigued types traumatic and burn, our we as are injuries. expanding pain
programs these data and platform the to will our We pathway clinical are on our are exosome development hopeful us delighted define help work that with technology.
delivery of the that are we as Additionally, programs vehicles. other exosomes have underway exploring use
to-date. are updating early are stage we progress as We that exosome been the by but working these in platform the have paths most programs on these exciting the look Now to forward new make with development, we technology. of you of on projects some far pre-clinically
program be for every of for had we in exosome the also technologies. enthusiastic reason about development our CAP-XXXX the Duchenne both and While to
from raising analysis, data Bergman analysis we currently strategy HOPE-X capital in the resources have with we then, thank terms complete at to options complete will will who And you potentially not also continue I our the CFO, the be evaluate Once our the financials progress our to you our the trial. do time. our AJ we better interim We the per to the to spoke earlier, interim original look for time. to in it recognize will will also the to HOPE-X. forward I able Again, back program. updating we this now turn We protocol. review we delineate complete your of and that exosome trial of
